TLIS חוב כולל להון Talis Biomedical Corp.

The Talis Biomedical (TLIS) rapid testing ecosystem is undergoing a painful restructuring due to regulatory challenges and the loss of customers. Meanwhile, Talis Biomedical is developing cloud services for rapid tests, generating revenue through the sale of consumables and instruments. The price history on GURU.Markets shows that the total debt-to-equity ratio is 0.40, while a broad line of infection diagnostic panels effectively mitigates seasonality risks.

The total debt-to-equity ratio measures the proportion of borrowed funds relative to shareholders' equity, determining financial leverage and the extent of the business's dependence on external creditors. By analyzing the total debt/equity chart, an investor can identify the risk of a mismatch between the debt load of Talis Biomedical (TLIS) and its current state of total R&D pipeline stagnation and the cessation of commercial operations for the Talis One platform.